Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Q24240522)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (English)

0 references

0 references

1 reference

1 reference

1

Shelley R Salpeter

0 references

author name string

Elizabeth Greyber

series ordinal

2

0 references

Gary A Pasternak

series ordinal

3

0 references

Edwin E Salpeter (posthumous)

series ordinal

4

0 references

publication date

20 January 2010

0 references

published in

0 references

cites work

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Influence of phenformin and metformin on exercise induced lactataemia in patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Short-term effects of metformin in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, pla

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The mushroom Agaricus Blazei Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of tolbutamide and metformin in elderly diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Ciclazindol: An oral agent with weight reducing properties and hypoglycaemic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved endothelial function with metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Repaglinide in combination therapy with metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of metformin and diet on plasma testosterone and leptin levels in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone reduces monocyte activation in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Addition of Benfluorex to Biguanide Improves Glycemic Control in Obese Non–Insulin-Dependent Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of combined therapies in treatment of secondary failure to glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Miglitol combined with metformin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

One-year acarbose treatment raises fasting serum acetate in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Combination of insulin and metformin in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of short‐term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Potential roles of erythropoietin in the management of anaemia and other complications diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin treatment in NIDDM patients with mild renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Circadian Variation of Glucose, Insulin, and Free Fatty Acids During Long-term Use of Oral Hypoglycaemic Agents in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Prevalence of risk determinants for metformin-associated lactic acidosis and metformin utilization in the study of health in pomerania

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Sucrose taken during mixed meal has no additional hyperglycaemic action over isocaloric amounts of starch in well-controlled diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Lessons from UK prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A comparative study of the glycemic control of various antidiabetic agents and the role of homocysteine in the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Lactic acidosis rates in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Biguanide-associated lactic acidosis. Case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Balancing risk and benefit with oral hypoglycemic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Contra-indications to metformin therapy are largely disregarded

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Lactate homeostasis and lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Clinical pharmacokinetics of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Incidence of lactic acidosis in metformin users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: Assessment by the artificial pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin-associated lactic acidosis in Sweden 1977-1991

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

COMBINED TRIAL OF ACETOHEXAMIDE AND TWO DIGUANIDE PREPARATIONS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

High and typical 18F-FDG bowel uptake in patients treated with metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin as secondary therapy in a defined population with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effect of metformin on glycaemic control in type 2 diabetes in daily practice: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Lactic acidosis in patients with diabetes treated with metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Determination of Plasma Metformin by a New Cation-Exchange HPLC Technique

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin in treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Epidemiology of adverse drug reactions to phenformin and metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

THE EFFECT OF METFORMIN ON WEIGHT LOSS IN OBESITY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin reduces systemic methylglyoxal levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Role of metformin accumulation in metformin-associated lactic acidosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Contraindications to metformin therapy in patients with NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin and lactic acidosis: guilt by association?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin and lipoprotein(a) levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Outcome of metformin-facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002967.PUB3

7 January 2021